Of more than 40,000 biomarkers actively studied in pre-clinical and clinical settings globally, fewer than 400 achieve regulatory qualification. The gap is not scientific. Discovery has never been faster: AI-powered frameworks now surface biomarker associations across genomic, proteomic, imaging, and real-world evidence datasets at a scale and speed that was unimaginable five years ago. The constraint is evidentiary infrastructure: the absence of a governed, scalable mechanism to translate discovered signals into the decision-grade evidence that qualification, trial design, and regulatory submission actually require. Every program that advances without it absorbs a compounding cost that never appears as a single budget line.
This whitepaper makes the case for a governed evidence layer as the most consequential data infrastructure investment a life sciences organization can make in 2026. It quantifies what ungoverned evidence costs across review cycles, AI program performance, and regulatory exposure. It presents proof from a Fortune 500 pharmaceutical engagement where the same governance operating model reduced lead times by up to 40% and eliminated retrospective audit reconstruction entirely. And it provides a board-ready KPI framework: seven metrics with Year 0 baselines and Year 1 targets, so leadership can measure, track, and demonstrate the return from the first quarter of deployment.
Download our whitepaper now.